|
[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Hossain, F., Majumder, S., Ucar, D.A., et al. (2018) Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. Frontiers in Immunology, 9, 1288. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Lu, Q., Chen, X., Wang, S., et al. (2020) Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies. OncoTargets and Therapy, 13, 9323-9331. [Google Scholar] [CrossRef]
|
|
[4]
|
Zhong, Z., Sanchez-Lopez, E. and Karin, M. (2016) Autophagy, In-flammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell, 166, 288-298. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 27, 450-461. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Tumeh, P.C., Harview, C.L., Yearley, J.H., et al. (2014) PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance. Nature, 515, 568-571. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Liu, R., Wei, H., Gao, P., et al. (2017) CD47 Promotes Ovarian Cancer Progression by Inhibiting Macrophage Phagocytosis. Oncotarget, 8, 39021-39032. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Forde, P.M., Chaft, J.E., Smith, K.N., et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England Journal of Medicine, 378, 1976-1986. [Google Scholar] [CrossRef]
|
|
[9]
|
Chew, H.Y., De Lima, P.O., Gonzalez Cruz, J.L., et al. (2020) En-docytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 180, 895-914.e27. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Pai, S., Bamodu, O.A., Lin, Y.K., et al. (2019) CD47-SIRPα Sig-naling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma. Cells, 8, 1658. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Hayat, S.M.G., Bianconi, V., Pirro, M., et al. (2020) CD47: Role in the Immune System and Application to Cancer Therapy. Cellular Oncology, 43, 19-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Veillette, A. and Chen, J. (2018) SIRPα-CD47 Immune Check-point Blockade in Anticancer Therapy. Trends in Immunology, 39, 173-184. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zhang, L. and Huang, H. (2016) Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment. Anti-Cancer Agents in Medic-inal Chemistry, 16, 658-667. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Gao, L., Chen, K., Gao, Q., et al. (2017) CD47 Defi-ciency in Tumor Stroma Promotes Tumor Progression by Enhancing Angiogenesis. Oncotarget, 8, 22406-22413. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Barclay, A.N. and Brown, M.H. (2006) The SIRP Family of Recep-tors and Immune Regulation. Nature Reviews Immunology, 6, 457-464. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Barclay, A.N. and Van den Berg, T.K. (2014) The Interaction between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target. Nature Reviews Immunology, 32, 25-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Liu, Y., Tong, Q., Zhou, Y., et al. (2007) Func-tional Elements on SIRPalpha IgV Domain Mediate Cell Surface Binding to CD47. Journal of Molecular Biology, 365, 680-693. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Yoshida, H., Tomiyama, Y., Oritani, K., et al. (2002) In-teraction between Src Homology 2 Domain Bearing Protein Tyrosine Phosphatase Substrate-1 and CD47 Mediates the Adhesion of Human B Lymphocytes to Nonactivated Endothelial Cells. Journal of Immunology, 168, 3213-3220. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Brooke, G., Holbrook, J.D., Brown, M.H., et al. (2004) Human Lymphocytes Interact Directly with CD47 through a Novel Member of the Signal Regulatory Protein (SIRP) Family. Journal of Immunology, 173, 2562-2570. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
N’Diaye, E.N. and Brown, E.J. (2003) The Ubiquitin-Related Protein PLIC-1 Regulates Heterotrimeric G Protein Function through Association with Gbetagamma. Journal of Cell Bi-ology, 163, 1157-1165. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Campbell, I.G., Freemont, P.S., Foulkes, W., et al. (1992) An Ovarian Tumor Marker with Homology to Vaccinia Virus Contains an IgV-Like Region and Multiple Transmembrane Domains. Cancer Research, 52, 5416-5420.
|
|
[22]
|
Goto, H., Kojima, Y., Matsuda, K., et al. (2014) Efficacy of Anti-CD47 Anti-body-Mediated Phagocytosis with Macrophages against Primary Effusion Lymphoma. European Journal of Cancer, 50, 1836-1846. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Cioffi, M., Trabulo, S., Hidalgo, M., et al. (2015) Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 21, 2325-2337. [Google Scholar] [CrossRef]
|
|
[24]
|
Casey, S.C., Tong, L., Li, Y., et al. (2016) MYC Regulates the Antitumor Immune Response through CD47 and PD-L1. Science, 352, 227-231. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Willingham, S.B., Volkmer, J.P., Gentles, A.J., et al. (2012) The CD47-Signal Regulatory Protein Alpha (SIRPa) Interaction Is a Therapeutic Target for Human Solid Tumors. Proceed-ings of the National Academy of Sciences of the United States of America, 109, 6662-6667. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Chao, M.P., Alizadeh, A.A., Tang, C., et al. (2010) Anti-CD47 An-tibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. Cell, 142, 699-713. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Yoshida, K., et al. (2015) CD47 Is an Adverse Prognostic Factor and a Therapeutic Target in Gastric Cancer. Cancer Medicine, 4, 1322-1333.
|
|
[28]
|
Murata, Y., Saito, Y., Kotani, T., et al. (2018) CD47-Signal Regulatory Protein α Signaling System and Its Application to Cancer Immunotherapy. Cancer Sci-ence, 109, 2349-2357. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Weiskopf, K., Jahchan, N.S., Schnorr, P.J., et al. (2016) CD47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small-Cell Lung Cancer. Journal of Clinical Investigation, 126, 2610-2620. [Google Scholar] [CrossRef]
|
|
[30]
|
Li, F., Lv, B., Liu, Y., et al. (2018) Blocking the CD47-SIRPα Axis by De-livery of Anti-CD47 Antibody Induces Antitumor Effects in Glioma and Glioma Stem Cells. Oncoimmunology, 7, e1391973. [Google Scholar] [CrossRef]
|
|
[31]
|
Chao, M.P., Alizadeh, A.A., Tang, C., et al. (2011) Thera-peutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. Cancer Research, 71, 1374-1384. [Google Scholar] [CrossRef]
|
|
[32]
|
Lin, Y., Yan, X.Q., Yang, F., et al. (2012) Soluble Extracellular Domains of Human SIRPα and CD47 Expressed in Escherichia coli Enhances the Phagocytosis of Leukemia Cells by Macrophages in Vitro. Protein Expression and Purification, 85, 109-116. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
McCracken, M.N., Cha, A.C. and Weissman, I.L. (2015) Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 “Don’t Eat Me” Signals. Clinical Cancer Research, 21, 3597-3601. [Google Scholar] [CrossRef]
|
|
[34]
|
Ring, N.G., Herndler-Brandstetter, D., Weiskopf, K., et al. (2017) Anti-SIRPα Antibody Immunotherapy Enhances Neutrophil and Macrophage Antitumor Activity. Proceedings of the National Academy of Sciences of the United States of America, 114, e10578-e10585. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Wang, C., Sun, C., Li, M., et al. (2021) Novel Fully Human An-ti-CD47 Antibodies Stimulate Phagocytosis and Promote Elimination of AML Cells. Journal of Cellular Physiology, 236, 4470-4481. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Wang, Y., Yin, C., Feng, L., et al. (2015) Ara-C and An-ti-CD47 Antibody Combination Therapy Eliminates Acute Monocytic Leukemia THP-1 Cells in Vivo and in Vitro. Ge-netics and Molecular Research, 14, 5630-5641. [Google Scholar] [CrossRef]
|
|
[37]
|
Kaur, S., Elkahloun, A.G., Singh, S.P., et al. (2016) A Func-tion-Blocking CD47 Antibody Suppresses Stem Cell and EGF Signaling in Triple-Negative Breast Cancer. Oncotarget, 7, 10133-10152. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Zhao, C.L., Yu, S., Wang, S.H., et al. (2018) Characterization of Cluster of Differentiation 47 Expression and Its Potential as a Therapeutic Target in Esophageal Squamous Cell Cancer. Oncology Letters, 15, 2017-2023. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., et al. (2000) Role of CD47 as a Marker of Self on Red Blood Cells. Science, 288, 2051-2054. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Autio, K.A., Boni, V., Humphrey, R.W., et al. (2020) Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Tox-icity for Use in Immuno-Oncology. Clinical Cancer Research, 26, 984-989. [Google Scholar] [CrossRef]
|
|
[41]
|
Pietsch, E.C., Dong, J., Cardoso, R., et al. (2017) An-ti-Leukemic Activity and Tolerability of Anti-Human CD47 Monoclonal Antibodies. Blood Cancer Journal, 7, e536. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Kauder, S.E., Kuo, T.C., Harrabi, O., et al. (2018) ALX148 Blocks CD47 and Enhances Innate and Adaptive Antitumor Immunity with a Favorable Safety Profile. PLoS ONE, 13, e0201832. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Lian, S., Xie, R., Ye, Y., et al. (2019) Simultaneous Blocking of CD47 and PD-L1 Increases Innate and Adaptive Cancer immune Responses and Cytokine Release. EBioMedicine, 42, 281-295. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Piccione, E.C., Juarez, S., Liu, J., et al. (2015) A Bispecific An-tibody Targeting CD47 and CD20 Selectively Binds and Eliminates Dual Antigen Expressing Lymphoma Cells. MAbs, 7, 946-56. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Zelenetz, A.D., Abramson, J.S., Advani, R.H., et al. (2010) NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas. Journal of the National Compre-hensive Cancer Network, 8, 288-334.
|
|
[46]
|
Salles, G., Barrett, M., Foà, R., et al. (2017) Rituximab in B-Cell Hemato-logic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 34, 2232-2273. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Buatois, V., Johnson, Z., Salgado-Pires, S., et al. (2018) Preclini-cal Development of a Bispecific Antibody That Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics, 17, 1739-1751. [Google Scholar] [CrossRef]
|
|
[48]
|
Vogel, A. and Saborowski, A. (2020) Current Strategies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma. Cancer Treatment Reviews, 82, Article ID: 101946. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Du, K., Li, Y., Liu, J., et al. (2021) A Bispecific Antibody Targeting GPC3 and CD47 Induced Enhanced Antitumor Efficacy against Dual Antigen-Expressing HCC. Molecular Therapy, 29, 1572-1584. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Gordon, S.R., Maute, R.L., Dulken, B.W., et al. (2017) PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity. Nature, 545, 495-499. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Wang, Y., Ni, H., Zhou, S., et al. (2021) Tumor-Selective Blockade of CD47 Signaling with a CD47/PD-L1 Bispecific Antibody for Enhanced Anti-Tumor Activity and Limited Toxicity. Cancer Immunology, Immunotherapy, 70, 365-376. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Bartel, D.P. (2004) MicroRNAs: Genomics, Biogenesis, Mech-anism, and Function. Cell, 116, 281-297. [Google Scholar] [CrossRef]
|
|
[53]
|
Zhao, Y., Yu, X., Tang, H., et al. (2020) MicroRNA-200a Promotes Phagocytosis of Macrophages and Suppresses Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma by Targeting CD47. BioMed Research International, 2020, Article ID: 3723781. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Suzuki, S., Yokobori, T., Tanaka, N., et al. (2012) CD47 Expression Regulated by the miR-133a Tumor Suppressor Is a Novel Prognostic Marker in Esophageal Squamous Cell Carcinoma. Oncology Reports, 28, 465-472. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Rothchild, A.C., Sissons, J.R., Shafiani, S., et al. (2016) MiR-155-Regulated Molecular Network Orchestrates Cell Fate in the Innate and Adaptive Immune Response to Myco-bacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 113, e6172-e6181. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Huang, W., Wang, W.T., Fang, K., et al. (2018) MIR-708 Promotes Phagocytosis to Eradicate T-ALL Cells by Targeting CD47. Molecular Cancer, 17, 12. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Tang, W., Qin, J., Tang, J., et al. (2013) Aberrant Reduction of MiR-141 Increased CD47/CUL3 in Hirschsprung’s Disease. Cellular Physiology and Biochemistry, 32, 1655-1667. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Tsai, L.M. and Yu, D. (2010) MicroRNAs in Common Diseases and Po-tential Therapeutic Applications. Clinical and Experimental Pharmacology and Physiology, 37, 102-107. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Yu, W.B., Ye, Z.H., Chen, X., et al. (2021) The Develop-ment of Small-Molecule Inhibitors Targeting CD47. Drug Discovery Today, 26, 561-568. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Oronsky, B., Paulmurugan, R., Foygel, K., et al. (2017) RRx-001: A Systemically Non-Toxic M2-to-M1 Macrophage Stimulating and Prosensitizing Agent in Phase II Clinical Trials. Expert Opinion on Investigational Drugs, 26, 109-119. [Google Scholar] [CrossRef] [PubMed]
|